Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that managed care organizations (MCOs) are stalling the insomnia drug market. According to a new PhysicianForum report entitled Insomnia: Current Treatment and Impact of New Market Entrants, MCOs frequently restrict the number of pills in Ambien prescriptions and 25% to 40% of MCOs indicated that they would not add a new nonbenzodiazepine to their formularies.

"Primary care physicians (PCPs) are ready to begin prescribing new nonbenzodiazepines such as Sepracor's Estorra, Pfizer/Neurocrine's Indiplon, and Sanofi-Synthelabo's Ambien CR immediately or within three months of launch in the United States," said Cheryl Bourque, analyst at Decision Resources. "However, HMOs predict that new insomnia agents will not be added to formularies for up to six months--in those cases where they will be added at all."

Insomnia: Current Treatment and Impact of New Market Entrants is based on a survey of 20 HMO pharmacy directors and 72 PCPs throughout the United States. Their responses were compared to assess similarities and differences in clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high volume-prescribing PCPs, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Use of Novel Agents and Expanding Prophylaxis will Triple the Drug Market for Venous Thromboembolism by 2013

View Now